{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/13086"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/13086","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Interactions of a covalently - linked antithrombin-heparin complex with components of the fibrinolytic pathway","abstract":"<p>Unfractionated heparin (UFH) is used as an adjunct during thrombolytic therapy. However, its use is associated with many clinical limitations, such as the inability to inhibit fibrin-bound coagulation factors, increasing the potential for sustained procoagulant activity. We have developed a covalent conjugate of antithrombin (AT) and heparin (ATH) with superior anticoagulant properties to those of UFH. Some advantages of ATH include enhanced inhibition of surface-bound enzymes and its ability to reduce the overall size and mass of clots <em>in vivo</em>. However, the potential interactions of UFH or ATH with the components of the fibrinolytic pathway are not well understood. Therefore, our study utilized discontinuous second order rate constant (<em>k<sub>2</sub></em>) assays to determine rates of inhibition of plasmin (Pn) in the presence or absence of fibrin by AT+UFH <em>vs.</em> ATH. In addition, we monitored the rates of Pn generation in a system comprised of preformed fibrin clots with the aim of evaluating the inhibitory effect of AT+UFH or ATH in this more native system. The <em>k<sub>2 </sub></em>values for the inhibition of Pn without fibrin were 5.74x10<sup>6</sup>±0.278x10<sup>6</sup> and 6.39x10<sup>6</sup>±0.588x10<sup>6</sup> for AT+UFH and ATH, respectively (p=0.36). In the presence of fibrin, the <em>k<sub>2 </sub></em>values decreased to 1.45x10<sup>6</sup>±0.0971x10<sup>6</sup> for AT+UFH and 3.07x10<sup>6</sup>±0.192x10<sup>6 </sup>for ATH (<em>p</em></p>","abstract_html":"&lt;p&gt;Unfractionated heparin (UFH) is used as an adjunct during thrombolytic therapy. However, its use is associated with many clinical limitations, such as the inability to inhibit fibrin-bound coagulation factors, increasing the potential for sustained procoagulant activity. We have developed a covalent conjugate of antithrombin (AT) and heparin (ATH) with superior anticoagulant properties to those of UFH. Some advantages of ATH include enhanced inhibition of surface-bound enzymes and its ability to reduce the overall size and mass of clots &lt;em&gt;in vivo&lt;/em&gt;. However, the potential interactions of UFH or ATH with the components of the fibrinolytic pathway are not well understood. Therefore, our study utilized discontinuous second order rate constant (&lt;em&gt;k&lt;sub&gt;2&lt;/sub&gt;&lt;/em&gt;) assays to determine rates of inhibition of plasmin (Pn) in the presence or absence of fibrin by AT+UFH &lt;em&gt;vs.&lt;/em&gt; ATH. In addition, we monitored the rates of Pn generation in a system comprised of preformed fibrin clots with the aim of evaluating the inhibitory effect of AT+UFH or ATH in this more native system. The &lt;em&gt;k&lt;sub&gt;2 &lt;/sub&gt;&lt;/em&gt;values for the inhibition of Pn without fibrin were 5.74x10&lt;sup&gt;6&lt;/sup&gt;±0.278x10&lt;sup&gt;6&lt;/sup&gt; and 6.39x10&lt;sup&gt;6&lt;/sup&gt;±0.588x10&lt;sup&gt;6&lt;/sup&gt; for AT+UFH and ATH, respectively (p=0.36). In the presence of fibrin, the &lt;em&gt;k&lt;sub&gt;2 &lt;/sub&gt;&lt;/em&gt;values decreased to 1.45x10&lt;sup&gt;6&lt;/sup&gt;±0.0971x10&lt;sup&gt;6&lt;/sup&gt; for AT+UFH and 3.07x10&lt;sup&gt;6&lt;/sup&gt;±0.192x10&lt;sup&gt;6 &lt;/sup&gt;for ATH (&lt;em&gt;p&lt;/em&gt;&lt;/p&gt;","abstract_has_math":false,"creators":["Chander, Ankush"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Medical Sciences (Blood and Cardiovascular)","school":null,"contributors":[],"advisors":["Chan, Anthony K.C."],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013-10","date_published":"2013-10","updated_at":"2026-11-18T19:30:48Z","subjects":["Heparin","Fibrinolysis","Plasmin","Thrombosis","Thrombolysis","Coagulation","Biochemistry","Hematology","Medicinal and Pharmaceutical Chemistry"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/8489"],"render_values":[{"text":"https://doi.org/10.71548/8489","href":"https://doi.org/10.71548/8489","code":true}]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/7914","8955","4269717"],"render_values":[{"text":"opendissertations/7914","href":null,"code":true},{"text":"8955","href":null,"code":true},{"text":"4269717","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/13086","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/13086","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F13086","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Chan, Anthony K.C."]},{"key":"dc:contributor.department","label":"Department","values":["Medical Sciences (Blood and Cardiovascular)"]},{"key":"dc:creator","label":"Author","values":["Chander, Ankush"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-06-18T17:02:20Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-06-18T17:02:20Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2013-06-30"]},{"key":"dc:date.issued","label":"Date","values":["2013-10"]},{"key":"dc:type","label":"Dc Type","values":["thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Heparin","Fibrinolysis","Plasmin","Thrombosis","Thrombolysis","Coagulation","Biochemistry","Hematology","Medicinal and Pharmaceutical Chemistry"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/7914","8955","4269717"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/13086","https://doi.org/10.71548/8489"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["<p>Unfractionated heparin (UFH) is used as an adjunct during thrombolytic therapy. However, its use is associated with many clinical limitations, such as the inability to inhibit fibrin-bound coagulation factors, increasing the potential for sustained procoagulant activity. We have developed a covalent conjugate of antithrombin (AT) and heparin (ATH) with superior anticoagulant properties to those of UFH. Some advantages of ATH include enhanced inhibition of surface-bound enzymes and its ability to reduce the overall size and mass of clots <em>in vivo</em>. However, the potential interactions of UFH or ATH with the components of the fibrinolytic pathway are not well understood. Therefore, our study utilized discontinuous second order rate constant (<em>k<sub>2</sub></em>) assays to determine rates of inhibition of plasmin (Pn) in the presence or absence of fibrin by AT+UFH <em>vs.</em> ATH. In addition, we monitored the rates of Pn generation in a system comprised of preformed fibrin clots with the aim of evaluating the inhibitory effect of AT+UFH or ATH in this more native system. The <em>k<sub>2 </sub></em>values for the inhibition of Pn without fibrin were 5.74x10<sup>6</sup>±0.278x10<sup>6</sup> and 6.39x10<sup>6</sup>±0.588x10<sup>6</sup> for AT+UFH and ATH, respectively (p=0.36). In the presence of fibrin, the <em>k<sub>2 </sub></em>values decreased to 1.45x10<sup>6</sup>±0.0971x10<sup>6</sup> for AT+UFH and 3.07x10<sup>6</sup>±0.192x10<sup>6 </sup>for ATH (<em>p</em></p>"]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Science (MS)"]},{"key":"dc:title","label":"Title","values":["Interactions of a covalently - linked antithrombin-heparin complex with components of the fibrinolytic pathway"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Chan, Anthony K.C."],"dc:contributor.department":["Medical Sciences (Blood and Cardiovascular)"],"dc:creator":["Chander, Ankush"],"dc:date.accessioned":["2014-06-18T17:02:20Z"],"dc:date.available":["2014-06-18T17:02:20Z"],"dc:date.created":["2013-06-30"],"dc:date.issued":["2013-10"],"dc:description.abstract":["<p>Unfractionated heparin (UFH) is used as an adjunct during thrombolytic therapy. However, its use is associated with many clinical limitations, such as the inability to inhibit fibrin-bound coagulation factors, increasing the potential for sustained procoagulant activity. We have developed a covalent conjugate of antithrombin (AT) and heparin (ATH) with superior anticoagulant properties to those of UFH. Some advantages of ATH include enhanced inhibition of surface-bound enzymes and its ability to reduce the overall size and mass of clots <em>in vivo</em>. However, the potential interactions of UFH or ATH with the components of the fibrinolytic pathway are not well understood. Therefore, our study utilized discontinuous second order rate constant (<em>k<sub>2</sub></em>) assays to determine rates of inhibition of plasmin (Pn) in the presence or absence of fibrin by AT+UFH <em>vs.</em> ATH. In addition, we monitored the rates of Pn generation in a system comprised of preformed fibrin clots with the aim of evaluating the inhibitory effect of AT+UFH or ATH in this more native system. The <em>k<sub>2 </sub></em>values for the inhibition of Pn without fibrin were 5.74x10<sup>6</sup>±0.278x10<sup>6</sup> and 6.39x10<sup>6</sup>±0.588x10<sup>6</sup> for AT+UFH and ATH, respectively (p=0.36). In the presence of fibrin, the <em>k<sub>2 </sub></em>values decreased to 1.45x10<sup>6</sup>±0.0971x10<sup>6</sup> for AT+UFH and 3.07x10<sup>6</sup>±0.192x10<sup>6 </sup>for ATH (<em>p</em></p>"],"dc:description.degree":["Master of Science (MS)"],"dc:identifier.other":["opendissertations/7914","8955","4269717"],"dc:identifier.uri":["http://hdl.handle.net/11375/13086","https://doi.org/10.71548/8489"],"dc:subject":["Heparin","Fibrinolysis","Plasmin","Thrombosis","Thrombolysis","Coagulation","Biochemistry","Hematology","Medicinal and Pharmaceutical Chemistry"],"dc:title":["Interactions of a covalently - linked antithrombin-heparin complex with components of the fibrinolytic pathway"],"dc:type":["thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:30:48Z"}